CME Group Cl A shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

CME Group posts strong earnings on growing trading volumes and margins. Learn the risks, market opportunities, and why it's ...

CME Group will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line ...

CME Group is growing new products, markets, and users, as well as having achieved profit margins beating its sector and key ...

What Happened: In a significant move reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, Suskind purchased 532 shares of CME Group, demonstrating confidence in ...

CME Group's Financial Performance Revenue Growth: Over the 3 months period, CME Group showcased positive performance, achieving a revenue growth rate of 10.38% as of 31 March, 2025.

Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization. CME Group: Financial Performance Dissected ...

CME's historical dominance is underpinned by a legacy of product launches dating back to the 1800s, and its stock has dramatically outperformed the S&P 500 since its 2002 IPO, delivering a 20% CAGR.

We came across a bullish thesis on CME Group Inc. on Special Situation Investing’s Substack by Six Bravo. In this article, we will summarize the bulls’ thesis on CME.

CME Group has announced that it will introduce FTSE CoreCommodity CRB Index futures on July 21, pending regulatory approval. The new contracts will be ...